272 related articles for article (PubMed ID: 17456057)
1. Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation.
Nishio M; Fujimoto K; Yamamoto S; Endo T; Sakai T; Obara M; Kumano K; Yamaguchi K; Takeda Y; Goto H; Sato N; Koizumi K; Mukai M; Koike T
Br J Haematol; 2007 May; 137(4):349-54. PubMed ID: 17456057
[TBL] [Abstract][Full Text] [Related]
2. Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma.
Nishio M; Fujimoto K; Yamamoto S; Endo T; Sakai T; Obara M; Kumano K; Minauchi K; Yamaguchi K; Takeda Y; Sato N; Koizumi K; Mukai M; Koike T
Eur J Haematol; 2006 Sep; 77(3):226-32. PubMed ID: 16923109
[TBL] [Abstract][Full Text] [Related]
3. FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation.
Nishio M; Endo T; Fujimoto K; Yamamoto S; Obara M; Yamaguchi K; Takeda Y; Goto H; Kasahara I; Sato N; Koike T
Eur J Haematol; 2009 Feb; 82(2):143-7. PubMed ID: 19018870
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.
Tokunaga M; Fujii K; Saito K; Nakayamada S; Tsujimura S; Nawata M; Tanaka Y
Rheumatology (Oxford); 2005 Feb; 44(2):176-82. PubMed ID: 15494350
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma.
Shortt J; Spencer A
Bone Marrow Transplant; 2006 Sep; 38(6):433-6. PubMed ID: 16892074
[TBL] [Abstract][Full Text] [Related]
6. Impaired B-cell reconstitution in lymphoma patients undergoing allogeneic HSCT: an effect of pretreatment with rituximab?
Buser A; Stern M; Arber C; Medinger M; Halter J; Rovo A; Favre G; Lohri A; Tichelli A; Gratwohl A
Bone Marrow Transplant; 2008 Oct; 42(7):483-7. PubMed ID: 18695668
[TBL] [Abstract][Full Text] [Related]
7. Delayed acquisition of somatic hypermutations in repopulated IGD+CD27+ memory B cell receptors after rituximab treatment.
Muhammad K; Roll P; Einsele H; Dörner T; Tony HP
Arthritis Rheum; 2009 Aug; 60(8):2284-93. PubMed ID: 19644860
[TBL] [Abstract][Full Text] [Related]
8. Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma.
Martin P; Furman RR; Ruan J; Elstrom R; Barrientos J; Niesvizky R; Coleman M; Leonard JP
Semin Hematol; 2008 Apr; 45(2):126-32. PubMed ID: 18381108
[TBL] [Abstract][Full Text] [Related]
9. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505
[TBL] [Abstract][Full Text] [Related]
10. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients.
Ansell SM; Geyer SM; Maurer MJ; Kurtin PJ; Micallef IN; Stella P; Etzell P; Novak AJ; Erlichman C; Witzig TE
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6056-63. PubMed ID: 17062681
[TBL] [Abstract][Full Text] [Related]
12. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis.
Roll P; Palanichamy A; Kneitz C; Dorner T; Tony HP
Arthritis Rheum; 2006 Aug; 54(8):2377-86. PubMed ID: 16869000
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy with rituximab/interleukin-2 after autologous stem cell transplantation as treatment for CD20+ non-Hodgkin's lymphoma.
Holmberg LA; Maloney D; Bensinger W
Clin Lymphoma Myeloma; 2006 Sep; 7(2):135-9. PubMed ID: 17026825
[TBL] [Abstract][Full Text] [Related]
14. IL-27 induces the production of IgG1 by human B cells.
Boumendjel A; Tawk L; Malefijt Rde W; Boulay V; Yssel H; Pène J
Eur Cytokine Netw; 2006 Dec; 17(4):281-9. PubMed ID: 17353163
[TBL] [Abstract][Full Text] [Related]
15. [Preliminary assessment of immune reconstitution after autologous peripheral hematopoietic stem cell transplantation (AHSCT)].
Huang HQ; Cai QC; Shi YX; Lin XB; Wei J; Guo Y; Pan ZH
Ai Zheng; 2006 Aug; 25(8):1023-8. PubMed ID: 16965687
[TBL] [Abstract][Full Text] [Related]
16. Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin's lymphoma patients receiving autologous hematopoietic stem cell transplantation.
Lee MY; Chiou TJ; Hsiao LT; Yang MH; Lin PC; Poh SB; Yen CC; Liu JH; Teng HW; Chao TC; Wang WS; Chen PM
Ann Hematol; 2008 Apr; 87(4):285-9. PubMed ID: 17943285
[TBL] [Abstract][Full Text] [Related]
17. Absence of IgD-CD27(+) memory B cell population in X-linked hyper-IgM syndrome.
Agematsu K; Nagumo H; Shinozaki K; Hokibara S; Yasui K; Terada K; Kawamura N; Toba T; Nonoyama S; Ochs HD; Komiyama A
J Clin Invest; 1998 Aug; 102(4):853-60. PubMed ID: 9710455
[TBL] [Abstract][Full Text] [Related]
18. [Rituximab].
Okamoto R; Maeda Y; Sasaki T
Gan To Kagaku Ryoho; 2003 Aug; 30(8):1085-93. PubMed ID: 12938262
[TBL] [Abstract][Full Text] [Related]
19. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease.
Younes A; Romaguera J; Hagemeister F; McLaughlin P; Rodriguez MA; Fiumara P; Goy A; Jeha S; Manning JT; Jones D; Abruzzo LV; Medeiros LJ
Cancer; 2003 Jul; 98(2):310-4. PubMed ID: 12872350
[TBL] [Abstract][Full Text] [Related]
20. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny.
Anolik JH; Friedberg JW; Zheng B; Barnard J; Owen T; Cushing E; Kelly J; Milner EC; Fisher RI; Sanz I
Clin Immunol; 2007 Feb; 122(2):139-45. PubMed ID: 17008130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]